Peanut

Overview

Peanut allergenic extract is used in allergenic testing.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy	2024/03/06	NCT06297083	Phase 2	Withdrawn	Murdoch Childrens Research Institute
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age	2023/02/23	NCT05741476	Phase 3	Active, not recruiting	DBV Technologies
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects	2022/07/27	NCT05476497	Phase 1	Recruiting	Allergy Therapeutics
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy	2022/07/01	NCT05440643	Phase 1	Active, not recruiting	ALK-Abelló A/S
Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy	2021/07/23	NCT04974970	Phase 1	Terminated	University Hospital, Geneva
Viaskin® Peanut (DBV712) Expanded Access Protocol	2020/05/01	NCT04371627	N/A	NO_LONGER_AVAILABLE	DBV Technologies
Food Oral Immunotherapy for Peanut Allergy	2020/01/10	NCT04222491	Phase 2	ENROLLING_BY_INVITATION	Massachusetts General Hospital
Boiled Peanut Oral Immunotherapy	2019/09/16	NCT04090203	Phase 1	Active, not recruiting	Alton Melton
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy	2019/04/09	NCT03907397	Phase 2	Completed	Scott Sicherer
Peanuts and Glycemic Control	2018/08/31	NCT03654651	Phase 2	Completed	Penn State University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
PALFORZIA (Level 4)	Aimmune Therapeutics	71881-104	ORAL	20 mg in 1 1	3/17/2023
PALFORZIA (Level 11)	Aimmune Therapeutics	71881-111	ORAL	300 mg in 1 1	3/17/2023
Peanut	Antigen Laboratories, Inc.	49288-0379	SUBCUTANEOUS, INTRADERMAL	0.05 g in 1 mL	11/17/2009
PEANUT FOOD	Allergy Laboratories, Inc.	54575-433	PERCUTANEOUS, SUBCUTANEOUS	1 g in 20 mL	3/15/2011
Peanut	Nelco Laboratories, Inc.	36987-1551	INTRADERMAL, SUBCUTANEOUS	0.05 g in 1 mL	12/9/2009
PALFORZIA (Level 6)	Aimmune Therapeutics	71881-106	ORAL	80 mg in 1 1	3/17/2023
PALFORZIA (Level 2)	Aimmune Therapeutics	71881-102	ORAL	6 mg in 1 1	3/17/2023
PALFORZIA (Level 5)	Aimmune Therapeutics	71881-105	ORAL	40 mg in 1 1	3/17/2023
Peanut	Nelco Laboratories, Inc.	36987-1550	INTRADERMAL, SUBCUTANEOUS	0.05 g in 1 mL	12/9/2009
Peanut	Nelco Laboratories, Inc.	36987-1553	INTRADERMAL, SUBCUTANEOUS	0.1 g in 1 mL	12/9/2009

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Viaskin Peanut Patch Shows Promise in Toddlers with Peanut Allergy, Gains FDA Accelerated Approval Pathway

9 months ago

DBV Technologies' Viaskin Peanut patch demonstrates sustained benefits over 36 months in toddlers aged 1-3, improving treatment efficacy and safety.

SEAL Trial Aims to Prevent Food Allergies in Children by Targeting Eczema

a year ago

• The SEAL clinical trial is enrolling infants up to 12 weeks old with dry skin or eczema to assess early intervention strategies. • The trial will evaluate whether targeting the skin of children with eczema can prevent the development of food allergies. • Participants will be treated with moisturizers, with one group receiving steroids only during flare-ups and the other receiving continuous steroid treatment. • The study will follow participants for two years, including food allergy testing and oral food challenges to assess the effectiveness of the interventions.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access